BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1012 related articles for article (PubMed ID: 32601974)

  • 21. Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.
    Xu X; Liu R; He A; Wang F
    Hematology; 2023 Dec; 28(1):2265206. PubMed ID: 37796109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Chen N; Pan J; Zhou Y; Mao L; Lou Y; Qian J; Xu G; Wei J; Zhou D; Shou L; Huang L; Yan M; Zeng H; Fan C; Wu G; Feng W; Tong H; Jin J; Wang H
    Br J Haematol; 2024 Mar; 204(3):861-870. PubMed ID: 37939390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress in the problem of relapsed or refractory acute myeloid leukemia.
    Mims AS; Blum W
    Curr Opin Hematol; 2019 Mar; 26(2):88-95. PubMed ID: 30640734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation.
    Xuan L; Wang Y; Chen J; Jiang E; Gao L; Wu B; Deng L; Liang X; Huang F; Fan Z; Tang X; Sun J; Zhang X; Han M; Wu D; Huang X; Liu Q
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1674-1681. PubMed ID: 31009704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How I treat refractory and early relapsed acute myeloid leukemia.
    Thol F; Schlenk RF; Heuser M; Ganser A
    Blood; 2015 Jul; 126(3):319-27. PubMed ID: 25852056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
    Bewersdorf JP; Stahl M; Zeidan AM
    Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Acute leukemia in adults].
    Eigendorff E; Hochhaus A
    Pathologe; 2015 Sep; 36(5):503-17; quiz 518-9. PubMed ID: 26314268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
    Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
    Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
    Stone RM
    Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
    Madero-Marroquin R; DuVall AS; Saygin C; Wang P; Gurbuxani S; Larson RA; Stock W; Patel AA
    Br J Haematol; 2024 Apr; 204(4):1238-1242. PubMed ID: 38073116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
    Yamauchi T
    Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
    Huemer F; Melchardt T; Jansko B; Wahida A; Jilg S; Jost PJ; Klieser E; Steiger K; Magnes T; Pleyer L; Greil-Ressler S; Rass C; Greil R; Egle A
    Eur J Haematol; 2019 May; 102(5):437-441. PubMed ID: 30725494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
    Zhao J; Song Y; Liu D
    Biomark Res; 2019; 7():19. PubMed ID: 31528345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress and predictions: AML in 2018.
    Rowe JM
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
    Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
    Risueño A; See WL; Bluemmert I; de Botton S; DiNardo CD; Fathi AT; Schuh AC; Montesinos P; Vyas P; Prebet T; Gandhi A; Hasan M
    Leuk Res; 2024 May; 140():107497. PubMed ID: 38564986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
    Montesinos P; Bergua J; Infante J; Esteve J; Guimaraes JE; Sierra J; Sanz MÁ
    Ann Hematol; 2019 Nov; 98(11):2467-2483. PubMed ID: 31667544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
    Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.